Evidence map›Paper›PMID 33069080›Full record

ArticleBioorganic & medicinal chemistry2020

Allosteric kidney-type glutaminase (GLS) inhibitors with a mercaptoethyl linker.

Bridget Duvall, Sarah C Zimmermann, Run-Duo Gao, Ajit G Thomas, Filip Kalčic, Vijayabhaskar Veeravalli, Amira Elgogary, Rana Rais, Camilo Rojas, Anne Le and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. The Glutaminase-1 Inhibitor [Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  5. Review
  6. The Role of Glutamine and Glutaminase in Pulmonary Hypertension.Frontiers in cardiovascular medicine · 2022
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bridget DuvallJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, USA.
Sarah C ZimmermannJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, USA.
Run-Duo GaoJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, USA.
Ajit G ThomasJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, USA.
Filip KalčicJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, USA.
Vijayabhaskar VeeravalliJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, USA.
Amira ElgogaryDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21205, USA.
Rana RaisJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, USA.
Camilo RojasJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, USA; Department of Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, MD 21205, USA.
Anne LeDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21205, USA.
Barbara S SlusherJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, USA.
Takashi TsukamotoJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, USA. Electronic address: ttsukamoto@jhmi.edu.

Funding

Therapeutic CoreP30MH075673 · NIMH · JOHNS HOPKINS UNIVERSITY · PI Leah Helane Rubin, Barbara Stauch Slusher · 2006 to 2026
$33.2M
Translational Research in Neuro-AIDS and Mental HealthR25MH080661 · NIMH · JOHNS HOPKINS UNIVERSITY · PI MCARTHUR, JUSTIN CHARLES. · 2007 to 2019
$2.9M
Glutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer TherapyR01CA193895 · NCI · JOHNS HOPKINS UNIVERSITY · PI HANES, JUSTIN S., LE, ANNE · 2016 to 2020
$2.1M
Novel Therapeutic Agents for Gliomas with IDH MutationsR21NS074151 · NINDS · JOHNS HOPKINS UNIVERSITY · PI TSUKAMOTO, TAKASHI · 2011 to 2012
$492k
Novel BPTES Analogs for the Treatment of Pancreatic CancerF32CA200278 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZIMMERMANN, SARAH · 2015 to 2017
$121k
NCI NIH HHS F32 CA200278NCI NIH HHS R01 CA193895NIMH NIH HHS P30 MH075673NIMH NIH HHS R25 MH080661NINDS NIH HHS R21 NS074151
6 · The paper itself

Abstract

A series of allosteric kidney-type glutaminase (GLS) inhibitors possessing a mercaptoethyl (SCH

Indexed as

Allosteric SiteBenzene DerivativesDose-Response Relationship, DrugEnzyme InhibitorsGlutaminaseHumansKidneyMolecular StructureSolubilityStructure-Activity RelationshipSulfhydryl CompoundsBenzene DerivativesEnzyme InhibitorsGlutaminaseSulfhydryl CompoundsAllosteric inhibitorBPTESCB-839GLSGlutaminaseThioethyl linker

Identifiers

PMID33069080
PMCPMC9115729

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.